Abstract
Painful peripheral neuropathies resulting from cancer chemotherapy treatment is frequently dose-dependent and may diminish following dose reduction or termination of chemotherapy. However, dose reduction or treatment termination could lead to reemergence of the cancer. In addition, chemotherapy-induced peripheral neuropathy (CIPN) may persist long after termination of chemotherapy. Thus, there is a need for treatments to ameliorate pain during the course of an effective cancer treatment regimen. Because the mechanism underlying CIPN has yet to be fully characterized, there is a current lack of effective treatments for CIPN. Preclinical studies in CIPN rodent models have suggested a number of potential neuropathological mechanisms, which could serve as platforms for the development of novel therapeutics. Although a number of potential analgesic therapies have demonstrated robust efficacy in preclinical studies, rigorous clinical testing has yet to fully validate the preclinical findings. The lack of congruence between preclinical and clinical findings could be in part due to the phylogenetic distance between the main model species and humans. Thus, a CIPN model in nonhuman primates could serve to bridge the translational gap between laboratory findings in small animals and clinical utility. The current review points out the short comings of current CIPN rodent models and suggests the use of large animals, such as the nonhuman primate, to narrow the translational gap between preclinical and clinical findings and the discovery of novel therapeutics.
Keywords: Neuropathic pain, preclinical animal disease models, translational science, allodynia, clinical relevance.
CNS & Neurological Disorders - Drug Targets
Title:Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models
Volume: 15 Issue: 1
Author(s): Aldric Hama and Hiroyuki Takamatsu
Affiliation:
Keywords: Neuropathic pain, preclinical animal disease models, translational science, allodynia, clinical relevance.
Abstract: Painful peripheral neuropathies resulting from cancer chemotherapy treatment is frequently dose-dependent and may diminish following dose reduction or termination of chemotherapy. However, dose reduction or treatment termination could lead to reemergence of the cancer. In addition, chemotherapy-induced peripheral neuropathy (CIPN) may persist long after termination of chemotherapy. Thus, there is a need for treatments to ameliorate pain during the course of an effective cancer treatment regimen. Because the mechanism underlying CIPN has yet to be fully characterized, there is a current lack of effective treatments for CIPN. Preclinical studies in CIPN rodent models have suggested a number of potential neuropathological mechanisms, which could serve as platforms for the development of novel therapeutics. Although a number of potential analgesic therapies have demonstrated robust efficacy in preclinical studies, rigorous clinical testing has yet to fully validate the preclinical findings. The lack of congruence between preclinical and clinical findings could be in part due to the phylogenetic distance between the main model species and humans. Thus, a CIPN model in nonhuman primates could serve to bridge the translational gap between laboratory findings in small animals and clinical utility. The current review points out the short comings of current CIPN rodent models and suggests the use of large animals, such as the nonhuman primate, to narrow the translational gap between preclinical and clinical findings and the discovery of novel therapeutics.
Export Options
About this article
Cite this article as:
Hama Aldric and Takamatsu Hiroyuki, Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models, CNS & Neurological Disorders - Drug Targets 2016; 15 (1) . https://dx.doi.org/10.2174/1871527315666151110125325
DOI https://dx.doi.org/10.2174/1871527315666151110125325 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Isolation and Identification of Novel Neutrophil-Activating Cryptides Hidden in Mitochondrial Cytochrome c
Protein & Peptide Letters Small Neuroscience: The Nanostructure of the Central Nervous System and Emerging Nanotechnology Applications
Current Nanoscience Comparative Neurophysiologic Study of Pain in Patients with Parkinson's Disease and Patients with Persistent Pain After Spinal Surgery
Neuroscience and Biomedical Engineering (Discontinued) Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Editorial (Thematic Issue: Current Research and Clinical Application of Ultrasound Imaging in Musculoskeletal System)
Current Medical Imaging Role for GABA and Glu Plasma Membrane Transporters in the Interplay of Inhibitory and Excitatory Neurotransmission
Current Topics in Medicinal Chemistry Depression Under the Perspective of Oxytocin
Central Nervous System Agents in Medicinal Chemistry Converging Perturbed Microvasculature and Microglial Clusters Characterize Alzheimer Disease Brain
Current Alzheimer Research Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches
Current Pharmaceutical Design The ORL-1 Receptor System: Are There Opportunities for Antagonists in Pain Therapy?
Current Topics in Medicinal Chemistry Opening New Scenarios for Human MAO Inhibitors
Central Nervous System Agents in Medicinal Chemistry Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?
Current Pharmaceutical Design Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
Current Medicinal Chemistry The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View
Current Alzheimer Research Evaluation of Associated Genes with Traumatic Pain: A Systematic Review
CNS & Neurological Disorders - Drug Targets Controlling Apoptosis by Inhibition of Caspases
Current Medicinal Chemistry Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine Subject Index to Volume 10
Current Pharmaceutical Design